Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women

Journal of Women's Health

Volumn 15, Issue 5, 2006, Pages 591-598

  Massad, L Stewart ^a   Evans, Charlesnika T ^b   Minkoff, Howard ^c   Watts, D Heather ^d   Greenblatt, Ruth M ^e   Levine, Alexandra M ^f   Anastos, Kathryn ^g   Young, Mary ^h   Seifer, David B ⁱ   Golub, Elizabeth ^j   Cohen, Mardge ^k  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g MONTEFIORE MEDICAL CENTER   (United States)

^h GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^k Jr Hospital of Cook County   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AMENORRHEA; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; OLIGOMENORRHEA; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SELF REPORT; SERODIAGNOSIS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CONFIDENCE INTERVALS; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MENSTRUATION DISTURBANCES; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; ODDS RATIO; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; WOMEN'S HEALTH;

EID: 33746122966     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.15.591     Document Type: Article

References (18)

1. Clark RA, Mulligan K, Stamenovic E, et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS Clinical Trials Group studies. J Infect Dis 2001;184;1325.
2. Minkoff HL, Eisenberger-Matityahu D, Feldman J, Burk R, Clarke L. Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. Am J Obstet Gynecol 1999; 180:824.
3. Harlow SD, Schuman P, Cohen M, et al. Effect of HIV on menstrual cycle length. J Acquir Immune Defic Syndr 2000;24:68.
4. Chirgwin KD, Feldman J, Mueyyirci-Delale O, Landesman S, Minkoff H. Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome. J AIDS 1996; 12:489.
5. Harlow SD, Cohen M, Ohmit SE, et al. Substance use and psychotherapeutic medications: A likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus. Am J Obstet Gynecol 2003;188:881.
6. Shah PN, Smith JR, Wells C, Barton SE, Kitchen VS, Steer PJ. Menstrual symptoms in women infected by the human immunodeficiency virus. Obstet Gynecol 1994;83;397.
7. Ellerbrock TV, Wright TC, Bush TJ, Dole P, Brudney K, Chiasson MA. Characteristics of menstruation in women infected with human immunodeficiency virus. Obstet Gynecol 1996;87:1030.
8. Cu-Uvin S, Wright DJ, Anderson D, et al. Hormonal levels among HIV-1-seropositive women compared with high-risk HIV-seronegative women during the menstrual cycle. J Womens Health 2000;9:857.
9. Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003;15;34:461.
10. Hinz S, McCormack D, van der Spuy ZM. Endocrine function in HIV-infected women. Gynecol Endocrinol 2002;16:33.
11. Cejtin HE, Jacobson L, Springer G, et al. Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS 2003;17: 1702.
12. Gange SJ, Barron Y, Greenblatt RM, et al. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health 2002;56:153.
13. Whitman S, Murphy J, Cohen M, Sherer R. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults and injection drug users, from 1995-1997. Arch Intem Med 2000;160:365.
14. Mahajan AP, Tashima KT, Bausserman LL, Flynn MM, Carpenter CC. Plateau in body habitus changes and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy: A 3.5-year study. J Acquir Immune Defic Syndr 2001;28:332.
15. Pernestorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001;15:725.
16. Barkan SE, Melnick SL, Martin-Preston S, et al The Women's Interagency HIV Study. Epidemiology 1998;9:117.
17. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: An observational cohort brings clinical sciences to the bench. Clin Diag Lab Immunol 2004;12:1013.
18. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(RR-5):1. Updated April 7, 2005. Available at aidsinfo.nih.gov/ guidelines/archive.asp Last accessed September 22, 2005.